精准影像医学专题 |
|
|
|
|
PET-CT与乳腺癌分子病理分型、治疗反应及预后的相关性研究进展 |
潘静颖, 何梦烨, 柯蔚, 胡梦琳, 王美芳, 沈朋 |
浙江大学医学院附属第一医院肿瘤内科, 浙江 杭州 310003 |
|
Advances on correlation of PET-CT findings with breast cancer molecular subtypes, treatment response and prognosis |
PAN Jingying, HE Mengye, KE Wei, HU Menglin, WANG Meifang, SHEN Peng |
Department of Medical Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China |
引用本文:
潘静颖 等. PET-CT与乳腺癌分子病理分型、治疗反应及预后的相关性研究进展[J]. 浙江大学学报(医学版), 2017, 46(5): 473-480.
PAN Jingying, HE Mengye, KE Wei, HU Menglin, WANG Meifang, SHEN Peng. Advances on correlation of PET-CT findings with breast cancer molecular subtypes, treatment response and prognosis. Journal of ZheJiang University(Medical Science), 2017, 46(5): 473-480.
链接本文:
http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2017.10.04
或
http://www.zjujournals.com/xueshu/med/CN/Y2017/V46/I5/473
|
[1] |
TOSS A, CRISTOFANILLI M. Molecular characterization and targeted therapeutic approaches in breast cancer[J/OL]. Breast Cancer Res,2015,17:60.
|
[2] |
TURAL D, KIVRAK S D, MUTLU H, et al. Is there any relation between PET-CT SUVmax value and prognostic factors in locally advanced breast cancer?[J]. J BUON,2015,20(5):1282-1286.
|
[3] |
GARCÍA VICENTE A M, SORIANO CASTREJÓN Á, LEÓN MARTÍN A, et al. Molecular subtypes of breast cancer:metabolic correlation with 18F-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging,2013,40(9):1304-1311.
|
[4] |
MIYAKE K K, NAKAMOTO Y, KANAO S, et al. Journal club:diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer[J]. AJR Am J Roentgenol,2014,203(2):272-279.
|
[5] |
KITAJIMA K, FUKUSHIMA K, MIYOSHI Y, et al. Association between 18F-FDG uptake and molecular subtype of breast cancer[J]. Eur J Nucl Med Mol Imaging,2015,42(9):1371-1377.
|
[6] |
LEE S S, BAE S K, PARK Y S, et al. Correlation of molecular subtypes of invasive ductal carcinoma of breast with glucose metabolism in FDG PET/CT:based on the recommendations of the St. Gallen Consensus Meeting 2013[J]. Nucl Med Mol Imaging,2017,51(1):79-85.
|
[7] |
DUFFY M J, HARBECK N, NAP M, et al. Clinical use of biomarkers in breast cancer:Updated guidelines from the European Group on Tumor Markers(EGTM)[J]. Eur J Cancer,2017,75:284-298.
|
[8] |
EVANGELISTA L, BARETTA Z, VINANTE L, et al. Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer[J]. Eur J Nucl Med Mol Imaging,2011,38(2):293-301.
|
[9] |
KOO H R, PARK J S, KANG K W, et al. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes[J]. Eur Radiol,2014,24(3):610-618.
|
[10] |
COKMERT S, TANRIVERDI O, KARAPOLAT I, et al. The maximum standardized uptake value of metastatic site in 18F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer:An Izmir Oncology Group study[J]. J BUON,2016,21(6):1410-1418.
|
[11] |
GOLDHIRSCH A, WINER E P, COATES A S, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol,2013,24(9):2206-2223.
|
[12] |
KAJÁRY K, TOKÉS T, DANK M, et al. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer[J]. Nucl Med Commun,2015,36(1):28-37.
|
[13] |
BASU S, CHEN W, TCHOU J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18fluorodeoxyglucose/positron emission tomography imaging parameters:a potentially useful method for disease characterization[J]. Cancer,2008,112(5):995-1000.
|
[14] |
GARCÍA VICENTE A M, SORIANO CASTREJÓN A, RELEA CALATAYUD F, et al. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer[J]. Rev Esp Med Nucl Imagen Mol,2012,31(6):308-314.
|
[15] |
GEMIGNANI M L, PATIL S, SESHAN V E, et al. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer[J]. J Nucl Med,2013,54(10):1697-1702.
|
[16] |
PETERSON L M, MANKOFF D A, LAWTON T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol[J]. J Nucl Med,2008,49(3):367-374.
|
[17] |
YANG Z, SUN Y, XU X, et al. The assessment of estrogen receptor status and its intratumoral heterogeneity in patients with breast cancer by using 18F-fluoroestradiol PET/CT[J]. Clin Nucl Med,2017,42(6):421-427.
|
[18] |
EVANGELISTA L, GUARNERI V, CONTE P F. 18F-fluoroestradiol positron emission tomography in breast cancer patients:systematic review of the literature & meta-analysis[J]. Curr Radiopharm,2016,9(3):244-257.
|
[19] |
MCKEAGE K, PERRY C M. Trastuzumab:a review of its use in the treatment of metastatic breast cancer overexpressing HER2[J]. Drugs,2002,62(1):209-243.
|
[20] |
CHANG A J, DESILVA R, JAIN S, et al. 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors[J]. Pharmaceuticals(Basel),2012,5(1):79-93.
|
[21] |
LAFOREST R, LAPI S E, OYAMA R, et al.[89Zr]Trastuzumab:evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer[J]. Mol Imaging Biol,2016,18(6):952-959.
|
[22] |
GEBHART G, LAMBERTS L E, WIMANA Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine(T-DM1):the ZEPHIR trial[J]. Ann Oncol,2016,27(4):619-624.
|
[23] |
NⅡKURA N, LIU J, HAYASHI N, et al. Loss of human epidermal growth factor receptor 2(HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors[J]. J Clin Oncol,2012,30(6):593-599.
|
[24] |
ULANER G A, HYMAN D M, ROSS D S, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT[J]. J Nucl Med,2016,57(10):1523-1528.
|
[25] |
MORTIMER J E, DEHDASHTI F, SIEGEL B A, et al. Metabolic flare:indicator of hormone responsiveness in advanced breast cancer[J]. J Clin Oncol,2001,19(11):27-97.
|
[26] |
DEHDASHTI F, MORTIMER J E, TRINKAUS K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer[J]. Breast Cancer Res Treat,2009,113(3):509-517.
|
[27] |
PETERSON L M, KURLAND B F, SCHUBERT E K, et al. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)[J]. Mol Imaging Biol,2014,16(3):431-440.
|
[28] |
LINDEN H M, STEKHOVA S A, LINK J M, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer[J]. J Clin Oncol,2006,24(18):2793-2799.
|
[29] |
VAN KRUCHTEN M, GLAUDEMANS A W J M, DE VRIES E F J, et al. Positron emission tomography of tumour[18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy[J]. Eur J Nucl Med Mol Imaging,2015,42(11):1674-1681.
|
[30] |
LIU Q, WANG C, LI P, et al. The role of (18)F-FDG PET/CT and MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer:a systematic review and meta-analysis[J]. Biomed Res Int,2016,37(46):23-32.
|
[31] |
WAHL R L, ZASADNY K, HELVIE M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography:initial evaluation[J]. J Clin Oncol,1993,11(11):2101-2111.
|
[32] |
HUMBERT O, COCHET A, COUDERT B, et al. Role of positron emission tomography for the monitoring of response to therapy in breast cancer[J]. Oncologist,2015,20(2):94-104.
|
[33] |
STAFFORD S E, GRALOW J R, SCHUBERT E K, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy[J]. Acad Radiol,2002,9(8):913-921.
|
[34] |
DOSE S J, BADER M, JENICKE L, et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET[J]. J Nucl Med,2005,46(7):1144-1150.
|
[35] |
COUTURIER O, JERUSALEM G, N'GUYEN J M, et al. Sequential positron emission tomography using[18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer[J]. Clin Cancer Res,2006,12(21):6437-6443.
|
[36] |
SHIMODA W, HAYASHI M, MURAKAMI K, et al. The relationship between FDG uptake in PET scans and biological behavior in breast cancer[J]. Breast Cancer,2007,14(3):260-268.
|
[37] |
AKIMOTO E, KADOYA T, KAJITANI K, et al. Role of 18F-PET/CT in predicting prognosis of patients with breast cancer after neoadjuvant chemotherapy[J]. Clin Breast Cancer,2017, pii:S1526-8209(17)30037-X.
|
[38] |
KIM T H, YOON J K, KANG D K, et al. Correlation between F-18 fluorodeoxyglucose positron emission tomography metabolic parameters and dynamic contrast-enhanced MRI-derived perfusion data in patients with invasive ductal breast carcinoma[J]. Ann Surg Oncol,2015,22(12):3866-3872.
|
[39] |
AOGI K, KADOYA T, SUGAWARA Y, et al. Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer[J]. Breast Cancer Res Treat,2015,150(1):209-217.
|
[40] |
NAKAJO M, KAJIYA Y, KANEKO T, et al. FDG PET/CT and diffusion-weighted imaging for breast cancer:prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion[J]. Eur J Nucl Med Mol Imaging,2010,37(11):2011-2020.
|
[41] |
SONG B I, HONG C M, LEE H J, et al. Prognostic value of primary tumor uptake on F-18FDG PET/CT in patients with invasive ductal breast cancer[J]. Nucl Med Mol Imaging,2011,45(2):117-124.
|
[42] |
YUE Y, CUI X, BOSE S, et al. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging[J]. Breast Cancer Res Treat,2015,153(3):607-616.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|